Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0AFVCC
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
wO2023232144A1ADC30
|
|||||
| Synonyms |
WO2023232144A1ADC30
Click to Show/Hide
|
|||||
| Organization |
CANWELL BIOTECH LIMITED
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4.61
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
WO2025015586A1, ADC25, Payload
|
Payload Info | ||||
| Therapeutic Target |
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
|
Target Info | ||||
| Linker Name |
SMCC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
(1r,4r)-N- (2- ((2- ((4- ((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)oxy)butyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)-4- ((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)cyclohexane-1-carboxamide
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Max Tumor Growth lnhibition value (TGl) (d) | > 50% | Positive TLR expression (TLR+++/++) | ||
| Method Description |
ADC30 was tested in mouse M38 CRC model in C57BL/6 mice, 3 mg/kg, QWx3, IV
|
||||
| In Vivo Model | Mouse MC38 CRC Model in C57BL/6 Mice | ||||
References